Literature DB >> 23054088

Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent.

Vaibhav Mundra1, Yan Lu, Michael Danquah, Wei Li, Duane D Miller, Ram I Mahato.   

Abstract

PURPOSE: Since our newly synthesized potent 5-indolyl derivative, (2-(1 H-Indol-5-yl) thiazol-4-yl) 3, 4, 5-trimethoxyphenyl methanone (LY293), to treat resistant melanoma was hydrophobic, our objective was to synthesize a biodegradable copolymer for formulating this drug into nanoparticles and to determine its anticancer activity and mechanism of action.
METHODS: Methoxy poly (ethylene glycol)-b-poly (carbonate-co-lactide) [mPEG-b-P (CB-co-LA)] was synthesized for formulating LY293 into nanoparticles by o/w emulsification and stabilization by solvent evaporation. Particle size, drug release profile, in vitro efficacy in multiple melanoma cells, and mechanism of action of drug-loaded nanoparticles were determined.
RESULTS: LY293-loaded nanoparticles with 170 nm mean size and 2.2 and 4.16% drug loading efficiently inhibited proliferation of A375 and B16F10 cells with IC(50) of 12.5 nM and 25 nM, respectively. LY293 circumvented multidrug resistance and inhibited proliferation of Pgp overexpressing MDA-MB435/LCC6 MDR1 melanoma cells. Upon treatment with LY293-loaded nanoparticles, A375 cells underwent cell cycle arrest in G2/M phase and apoptotic cell death. Immunofluorescence images showed inhibition of tubulin polymerization after treatment with LY293.
CONCLUSION: LY293-loaded mPEG-b-P (CB-co-LA) nanoparticles showed excellent efficacy and induced apoptosis in melanoma cells. These polyester/polycarbonate-based nanoparticles provided an excellent platform to deliver different poorly soluble drugs to melanoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054088      PMCID: PMC3646297          DOI: 10.1007/s11095-012-0881-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

2.  Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

Authors:  L Serrone; M Zeuli; F M Sega; F Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2000-03

3.  Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.

Authors:  Zhao Wang; Jianjun Chen; Jin Wang; Sunjoo Ahn; Chien-Ming Li; Yan Lu; Vivian S Loveless; James T Dalton; Duane D Miller; Wei Li
Journal:  Pharm Res       Date:  2012-03-13       Impact factor: 4.200

4.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; V Pozharov; J Kopecek
Journal:  J Control Release       Date:  1998-07-31       Impact factor: 9.776

5.  Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery.

Authors:  Michael Danquah; Tomoko Fujiwara; Ram I Mahato
Journal:  Biomaterials       Date:  2010-03       Impact factor: 12.479

6.  Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.

Authors:  Xiaowei Dong; Cynthia A Mattingly; Michael T Tseng; Moo J Cho; Yang Liu; Val R Adams; Russell J Mumper
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.

Authors:  Agop Y Bedikian; Carl Plager; Nicholas Papadopoulos; Omar Eton; Julie Ellerhorst; Theresa Smith
Journal:  Melanoma Res       Date:  2004-02       Impact factor: 3.599

Review 8.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

9.  Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100.

Authors:  Feng Li; Yan Lu; Wei Li; Duane D Miller; Ram I Mahato
Journal:  J Control Release       Date:  2010-01-07       Impact factor: 9.776

10.  Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.

Authors:  A Rahman; S R Husain; J Siddiqui; M Verma; M Agresti; M Center; A R Safa; R I Glazer
Journal:  J Natl Cancer Inst       Date:  1992-12-16       Impact factor: 13.506

View more
  9 in total

1.  Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.

Authors:  Souvik Banerjee; Kinsie E Arnst; Yuxi Wang; Gyanendra Kumar; Shanshan Deng; Lei Yang; Guo-Bo Li; Jinliang Yang; Stephen W White; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2018-02-12       Impact factor: 7.446

2.  Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.

Authors:  Vaibhav Mundra; Yang Peng; Virender Kumar; Wei Li; Duane D Miller; Ram I Mahato
Journal:  Drug Deliv Transl Res       Date:  2015-06       Impact factor: 4.617

3.  LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer.

Authors:  Di Wen; Deepak Chitkara; Hao Wu; Michael Danquah; Renukadevi Patil; Duane D Miller; Ram I Mahato
Journal:  Pharm Res       Date:  2014-05-02       Impact factor: 4.200

4.  Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment.

Authors:  Jitender Bariwal; Virender Kumar; Hao Chen; Rajan Sharma Bhattarai; Yang Peng; Wei Li; Ram I Mahato
Journal:  J Control Release       Date:  2019-07-19       Impact factor: 9.776

5.  X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.

Authors:  Souvik Banerjee; Foyez Mahmud; Shanshan Deng; Lingling Ma; Mi-Kyung Yun; Sayo O Fakayode; Kinsie E Arnst; Lei Yang; Hao Chen; Zhongzhi Wu; Pradeep B Lukka; Keyur Parmar; Bernd Meibohm; Stephen W White; Yuxi Wang; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2021-08-18       Impact factor: 8.039

Review 6.  Nanoparticle-mediated drug delivery for treating melanoma.

Authors:  Vaibhav Mundra; Wei Li; Ram I Mahato
Journal:  Nanomedicine (Lond)       Date:  2015-08-05       Impact factor: 5.307

7.  Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.

Authors:  Virender Kumar; Vaibhav Mundra; Ram I Mahato
Journal:  Pharm Res       Date:  2013-11-19       Impact factor: 4.200

8.  Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.

Authors:  Vinod Kumar; Amit Kumar Chaudhary; Yuxiang Dong; Haizhen A Zhong; Goutam Mondal; Feng Lin; Virender Kumar; Ram I Mahato
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

9.  Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer.

Authors:  Rajan Sharma Bhattarai; Virender Kumar; Svetlana Romanova; Jitender Bariwal; Hao Chen; Shanshan Deng; Vijaya R Bhatt; Tatiana Bronich; Wei Li; Ram I Mahato
Journal:  J Control Release       Date:  2020-09-30       Impact factor: 9.776

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.